## Title: COVID-19 Vaccine Perceptions and Uptake in a National Prospective Cohort of

1

2 **Essential Workers** 3 **AUTHORS** 4 Karen Lutrick, PhD 5 Family & Community Medicine, College of Medicine – Tucson, University of Arizona, Tucson, 6 7 Holly Groom, MPH 8 Center for Health Research, Kaiser Permanente Northwest, Portland, OR 9 10 Ashley L. Fowlkes, ScD 11 Epidemiology Prevention Branch, Influenza Division, Centers of Disease Control and 12 Prevention, Atlanta, GA 13 14 Kimberly Groover, PhD 15 Abt Associates, Atlanta, GA 16 17 Manjusha Gaglani, MBBS 18 Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, TX 19 20 21 Patrick Rivers, MPP 22 Family & Community Medicine, College of Medicine – Tucson, University of Arizona, Tucson, 23 AZ24 25 Allison L. Naleway, PhD 26 Center for Health Research, Kaiser Permanente Northwest, Portland, OR 27 28 Kimberly Nguyen, DrPH, MS 29 Assessment Branch, Immunization Services Division, Centers for Disease Control and 30 Prevention, Atlanta, GA 31 32 Meghan Herring, MPH 33 Abt Associates, Atlanta, GA 34 35 Kayan Dunnigan, MPH 36 Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, TX 37 38 Andrew Phillips, MD, MOH 39 Occupational and Environmental Health, School of Medicine, University of Utah, Salt Lake 40 City, UT 41 42 Joel Parker, MS 43 Epidemiology and Biostatistics, College of Public Health, University of Arizona, Tucson, AZ 44

46

47

48 49

50

5152

53

54

5556

57

58 59

60

61 62

63

64

65

66 67

68

69

70

71

72

73

74

75

76

77

78

Julie Mayo Lamberte, MSPH Epidemiology Prevention Branch, Influenza Division, Centers of Disease Control and Prevention, Atlanta, GA Khaila Prather, MPH Abt Associates, Atlanta, GA Matthew S. Thiese, PhD, MSPH Occupational and Environmental Health, School of Medicine, University of Utah, Salt Lake City, UT Zoe Baccam Epidemiology and Biostatistics, College of Public Health, University of Arizona, Tucson, AZ Harmony Tyner, MD, MPH St. Luke's Infectious Disease Associates, St. Luke's Hospital, Duluth, MN Sarang Yoon, DO, MOH Occupational and Environmental Health, School of Medicine, University of Utah, Salt Lake City, UT **ABSTRACT Introduction:** In a multi-center prospective cohort of essential workers, we assessed knowledge, attitudes, and practices (KAP) by vaccine intention, prior SARS-CoV-2 positivity, and occupation, and their impact on vaccine uptake over time. Methods: Initiated in July 2020, HEROES-RECOVER cohort provided sociodemographics and COVID-19 vaccination data. Using follow-up two surveys approximately three months apart, COVID-19 vaccine KAP, intention, and receipt was collected; the first survey categorized participants as reluctant, reachable, or endorsers. **Results:** A total of 4,803 participants were included in the analysis. Most (70%) were vaccine endorsers, 16% were reachable, and 14% were reluctant. By May 2021, 77% had received at least one vaccine dose. KAP responses strongly predicted vaccine uptake, particularly positive attitudes about safety (aOR=5.46, 95% CI: 1.4-20.8) and effectiveness (aOR=5.0, 95%

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

CI: 1.3-19.1). Participants prior SARS-CoV-2 infection were 22% less likely to believe the COVID-19 vaccine was effective compared with uninfected participants (aOR 0.78, 95% CI: 0.64-0.96). This was even more pronounced in first responders compared with other occupations, with first responders 42% less likely to believe in COVID-19 vaccine effectiveness (aOR=0.58, 95% CI 0.40-0.84). KAP responses shifted positively, with reluctant and reachable participant scores modestly increasing in positive responses for perceived vaccine effectiveness (7% and 12%, respectively) on the second follow-up survey; 25% of initially reluctant participants received the COVID-19 vaccine. **Discussion:** Our study demonstrates attitudes associated with COVID-19 vaccine uptake and a positive shift in attitudes over time. First responders, despite potential high exposure to SARS-CoV-2, and participants with a history of SARS-CoV-2 infection were more vaccine reluctant. **Conclusions:** COVID-19 vaccine KAP responses predicted vaccine uptake and associated attitudes improved over time. Perceptions of the COVID-19 vaccine can shift over time. Targeting messages about the vaccine's safety and effectiveness in reducing SARS-CoV-2 virus infection and illness severity may increase vaccine uptake for reluctant and reachable participants.

### **INTRODUCTION**

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

The SARS-CoV-2 pandemic has resulted in high levels of morbidity and mortality in the US. In response, a global effort to develop COVID-19 vaccines generated evidence leading to the U.S. Food and Drug Administration (FDA) authorizing COVID-19 vaccines under an Emergency Use Authorization (EUA) mechanism, beginning in mid-December 2020. Essential workers, including healthcare personnel (HCP), first responders, and other frontline workers (FW), may be at an increased risk of SARS-CoV-2 infection because of their high rates of contact with patients, coworkers, or the general public<sup>3-7</sup> and were prioritized to receive COVID-19 vaccines by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices during initial, staggered distribution. The COVID-19 vaccines have been shown to be safe and effective in adults and children ages 12 and older, but the initial high demand for vaccination has decreased. Prior to COVID-19 vaccine authorization and availability in December 2020, early studies in the United States (US) reported rates of willingness to receive the COVID-19 vaccine ranging widely from 40% to 75%. 9-18 Additionally, first responders and FW have reported lower rates of vaccine acceptance than HCP. 12,14 Common reasons for vaccine hesitancy included the novelty of the COVID-19 vaccines, concerns about potential adverse effects, and/or a distrust in government. 9-14 There is some indication that COVID-19 vaccine acceptance has changed over time in cross-sectional surveys. 12,19 It is unclear how individual vaccination intention has evolved as the public, has gained more information regarding symptoms and outcomes of COVID-19 disease and risks and benefits of vaccinations. Knowledge, attitudes, and practices (KAP) toward vaccination are often examined to understand factors associated with the acceptability of vaccines and inform strategies for

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

increasing vaccine uptake. 20 We have addressed these knowledge gaps with a multi-center prospective cohort of essential workers with the following objectives: 1) assess differences in KAP by vaccine intention, prior SARS-CoV-2 positivity, and occupation group; 2) examine KAP as predictors of vaccine uptake; and 3) assess individual-level change in KAP over time. **METHODS** Study Design & Population The HEROES-RECOVER studies represent a national network of prospective cohorts, including Arizona Healthcare, Emergency Response and Other Essential Workers Surveillance Study (HEROES) and Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) funded by the CDC with sites in Phoenix, Tucson, and other areas in Arizona; Miami, Florida; Duluth, Minnesota; Portland, Oregon; Temple, Texas; and Salt Lake City, Utah. Details of the protocols of the studies have been previously published.<sup>21</sup> Ongoing enrollment began in July 2020 and included HCP, first responders, and FW who worked at least 20 hours per week and had routine occupational exposure to coworkers or the public. Participants completed detailed epidemiologic surveys at enrollment and at approximately three-month intervals (Follow-up surveys 1 and 2); text message-based surveys were completed weekly and monitored illness or potential COVID-19 contact in the past 7 days. The study is ongoing, but for this analysis participants actively enrolled during the Follow-up 1 survey distribution were included, with their prior SARS-CoV-2 infection, COVID-19 vaccination, and KAP data through May 19, 2021 utilized for analysis. To identify SARS-CoV-2 infections, participants self-collected mid-turbinate nasal swabs weekly for SARS-CoV-2 RT-PCR testing and provided blood specimens at enrollment and every

time of enrollment.

subsequent three months (supplemental Figure 1 for study timing). Beginning in December 2020, participants were prompted to report uptake of COVID-19 vaccine; vaccine survey distribution was based on vaccine availability data from state and county health departments. Vaccination was verified by participant-provided vaccine cards, electronic medical records, or State Immunization Information Systems. All protocols were reviewed and approved by each site's Institutional Review Boards; study participants provided informed consent for all study activities.

\*\*Primary Outcomes\*\*

Vaccine intention and KAP questions were in two follow-up surveys: Follow-up survey 1 was distributed from late December 2020-February 2021, and Follow-up survey 2 -- from March 2021-May 2021. New enrollees during each follow-up period received the KAP questions at the

Vaccine intention was derived using participants' first response to the question, "What are the chances that you will get a COVID-19 vaccination?" and vaccination status at the time of Follow-up survey 1. Participants were grouped into three intention categories: 1) reluctant as those who answered, "almost zero chance", or "very small chance", and were unvaccinated, 2) reachable as those who answered "small chance", "do not know", or "moderate" and were unvaccinated, or 3) endorser as those who answered, "large chance", "very large chance", or "almost certain", or were vaccinated at Follow-up survey 1. New vaccine receipt after Follow-up survey 1 was monitored and the participants' vaccine intention group did not change based upon Follow-up survey 2 KAP responses.

Participants were asked six questions to assess the KAP constructs regarding COVID-19:

in the government, and perceived risk of becoming ill if they were not vaccinated (Table *I* Table *I*). Responses to each question were rated on a 5- to 7-level Likert scale indicating lowest to highest ranking.

### **Predictors and Confounders**

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

For models examining KAP differences and predictors of vaccination, sociodemographics, including gender, age, race, ethnicity, education, household income, occupation and occupational setting, and participant health status, including SARS-CoV-2 infection status, COVID-19 vaccination status, and medical history were included. HCP occupation categories are categorized as any individual that works in a hospital as "HCP inpatient", any individual that works in any outpatient healthcare facility or long-term care facility as "HCP other". We created two first responder categories: 1) firefighter (firefighters/EMS) and 2) other first responders (law enforcement, correctional officers, and border patrol). FW public-facing included individuals that work in education settings, retail, food service, and hospitality. Other FW include individuals that work in infrastructure, manufacturing, warehouse, utility, and transportation. In models examining Objectives 1 and 2, COVID-19 contact data were reported as the number of hours spent at work (1) in any setting and in direct contact with individuals with suspected or confirmed COVID-19 and (2) the general public in the past 7 days. They also indicated the percent of time protective equipment (PPE) was used during this contact. Participants were categorized as having had a SARS-CoV-2 infection prior to Follow-up survey 1 if they reported detection by antibody, antigen, or RT-PCR assay prior to enrollment, or if SARS-CoV-2 was detected by RT-PCR or an antibody test during the study. For Objectives 2 and 3 (KAP change over time), KAP responses (defined above) were used as the primary predictors of interest.

### Statistical Analysis

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

We included all participants who completed the Follow-up 1 survey. Continuous measurements were expressed as means and standard deviations or median and interquartile range, as appropriate. Counts and percentages were used for categorical variables. Likert scores were dichotomized for each KAP question, using responses greater than midpoint as positive associations and midpoint and lower than the midpoint as neutral/negative associations (Table 1). We stratified socio-demographics, occupation and occupational setting, previous positivity, KAP responses by vaccine intention, and utilized chi-squared tests or one-way ANOVA tests to examine family-wise differences between the vaccine intention groups, with statistical significance based on p-values <0.05. To examine KAP differences (Objective 1), we used unadjusted ordinal logistic regression to examine the relationship between each KAP question in the Follow-up 1 survey and vaccine intention, each occupation, and prior positivity. Bonferroni corrections adjusted for multiple comparisons and statistical significance based on 95% confidence intervals. We also used a difference in proportion test to test pair-wise differences in answers to KAP questions. For KAP predictors (Objective 2), we utilized adjusted ordinal logistic regression to test the effect of each KAP on vaccine uptake when including socio-demographics, occupation and occupational setting, vaccine intention, and prior positivity together. Bonferroni corrections adjusted for the multiple comparisons and statistical significance based on 95% confidence intervals. For KAP change (Objective 3), we tested differences in answers to KAP questions in Follow-up 2 compared to Follow-up 1 on a subset that completed both surveys. Chi-squared tests were used to determine statistically significant differences in each KAP question at Follow-up 2

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

compared to Follow-up 1, with significance based on p-values <0.05. We descriptively examined vaccine uptake and KAPs over time for each vaccine intention group. All statistical analyses were completed using R (version 4.0.4; R Foundation for Statistical Computing) and SAS (version 9.4; SAS Institute). **RESULTS** Overall Participants. December 2020 -February 2021, 4,803 (87%) of 5,527 participants responded to Follow-up survey 1; 1,105 (23%) HCP inpatient, 1,323 (28%) other HCP, 729 (15%) first responder firefighter, 255 (5%) other first responders, 990 (21%) FW Public, and 285 (6%) other FW (Table 2). Most participants were female (62%) and aged <45 years (58%). Additionally, 72% were non-Hispanic White, 14% Hispanic, 9% other, 3% Asian American/Pacific Islander, and 2% African American. Participants were highly educated, including 76% with at least a college degree, and only 15% percent reporting annual income less than \$50,000. Participants were healthy, with only 24% reporting an underlying condition, most commonly hypertension (12%), asthma (9%), and diabetes (3%). At the time of the Follow-up 1 survey, 960 (20%) of participants had previously been infected with SARS-CoV-2. Total positive rates amongst FW and HCP were similar (25% and 22% respectively), with higher rates amongst first responders (32%). Thirty-six percent had received a COVID-19 vaccination at the time of the Follow-up 1 survey. **Vaccination Intent.** Most participants were categorized as endorsers (70%), having either indicated a high likelihood of intent to receive the COVID-19 vaccine (35%) or having

already received it at the time of Follow-up 1 survey (36%); 16% of participants were considered

reachable, and 14% reluctant. Prior SARS-CoV-2 infection was more common among reluctant

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

(35%) and reachable participants (25%) compared with endorsers (16%). By May 19, 2021, 72% of participants hae received at least one dose of a COVID-19 vaccine (Table 2). Vaccine uptake varied by intention group, including reported COVID-19 vaccine receipt among 86% of endorsers, 53% of reachable, and 25% of reluctant. Objective 1: KAP as predictor for vaccine uptake After adjusting for socio-demographic factors, health status, and hours of direct contact with the public, KAP responses strongly predicted vaccine uptake. Participants reporting more positive attitudes about COVID-19 vaccine safety were 5.5 times more likely to receive a COVID-19 vaccine compared with those reporting more negative attitudes (aOR=5.46, 95% CI: 1.43-20.82) and 5 times as likely to receive a COVID-19 vaccine among participants reporting a belief that the vaccine is effective (aOR=4.98 95% CI: 1.30-19.14) (Table 3). Objective 2: KAP responses by intention group, prior SARS-CoV-2 infection and occupation **Vaccine Intention Groups.** Only 17% of reluctant (n=109) and 33% of reachable participants (n=252) reported concern about getting sick if unvaccinated compared with 48% of endorsers (n=1624) (Table 2). Similarly, reluctant and reachable participants were more likely to report negative attitudes about vaccine safety (82% and 56%, respectively), vaccine effectiveness (76% and 51%, respectively), and trust in the government (79% and 58%, respectively). Reachable participants were about half as likely and reluctant participants were substantially less likely to perceive the COVID-19 vaccines as safe compared to endorsers (aOR =0.56, 95% CI 0.31-1.00 and aOR=0.33, 95% CI: 0.28-0.38, respectively) (Error! Reference source not found.). Similarly, reluctant participants were 68% (aOR=0.32, 95% CI: 0.22-0.48) less likely than endorsers to perceive that the vaccine was effective. Interestingly, reachable

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

participants were less likely to report knowledge about the COVID-19 vaccine than reluctant participants (aOR=0.53, 95% CI: 0.30-0.96 and aOR=0.49 95% CI: 0.34-0.75, respectively). **Prior SARS-CoV-2 Infection.** Among 960 (20%) participants who reported SARS-CoV-2 infection prior to enrollment, 24% (n=229) were categorized as reluctant, 20% as reachable (n=194), and 56% (n=537) as endorsers (Table 2). COVID-19 vaccination through the study period was less common among participants with prior SARS-CoV-2 infection (n=576, 59%) compared to those without prior infection (n=3188, 82%). In the adjusted models, participants with prior SARS-CoV-2 infection were 32% less likely to be concerned about getting sick if not vaccinated (aOR 0.68, 95% CI: 0.56-0.84) and 22% less likely to believe the COVID-19 vaccine was effective (aOR 0.78, 95% CI: 0.64-0.96) compared with uninfected participants. Interestingly, there were no significant differences in perceived virus knowledge, vaccine safety, or trust in government by infection status in the adjusted models (Table 3). Occupation. Overall, few HCP were COVID-19 vaccine reluctant, including 9% of HCP inpatient and 11% other HCP. Among first responders, subcategorization showed slight differences, with 16% of firefighters reluctant compared with 21% of other first responders. Similarly, 16% of public-facing FW and 20% of other FW were reluctant. Responses to KAP questions differed across occupations but were aligned with overall responses for vaccine intent groups that combine participants. There was little difference between occupational subcategories of HCP or first responders in the adjusted models (Table 3Error! Reference source not found.). Firefighters and other first responder were each approximately 40% less likely than inpatient HCP to believe the COVID-19 vaccine was effective (aOR=0.58, 95% CI 0.40-0.84 and aOR=0.61, 95% CI 0.49-0.76, respectively). The other FW category was 51% more likely to believe the COVID-19 vaccine

was effective compared to inpatient HCP (aOR=1.49, 95% CI 1.26-1.77), followed by public-facing FW (aOR=1.25, 95% CI 1.02-1.53) (Error! Reference source not found.).

\*Objective 3. KAP change over time\*

To evaluate change in KAP over time, 2017 (49%) participants that completed both

Follow-up 1 and 2 surveys were included. Among initially 383 reluctant participants, 94 (25%) received COVID-19 vaccine; 195 (56%) reachable and 1,232 (83%) endorsers were also vaccinated. Demographic characteristics among reluctant and reachable participants who were vaccinated after initial categorization did not differ from unvaccinated participants. Among endorsers, unvaccinated participants were more likely to be male (p=0.017), younger (p=0.014)), and firefighters (p<0.001) than endorsers that were vaccinated (

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

Table ). When evaluating KAP over time, reluctant participants that did not get vaccinated had a 9% decrease in positive responses to questions about their knowledge of the virus between Follow-up survey 1 and 2 (Error! Reference source not found.). The change in positive response to vaccine knowledge increased by 20% and 21% for the non-vaccinated and vaccinated, respectively. However, there was a 7% increase in positive response toward vaccine effectiveness in those that were not vaccinated compared to a 31% increase for vaccinated participants. Participants in the reachable and endorser vaccine intent groups also showed decreases in positive responses for knowledge about the virus between the two time points (-19% and -22%, respectively), with higher percentages of participants reporting negative/neutral responses during Follow-up Survey 2 (Error! Reference source not found.). The reachable group had large increases in positive responses for questions about vaccine knowledge (25% of vaccinated, 25% of unvaccinated), vaccine safety (10% of vaccinated, 34% of unvaccinated), and vaccine effectiveness (12% of vaccinated, 27% of unvaccinated). **DISCUSSION** The HEROES-RECOVER prospective cohort provided a unique opportunity to examine COVID-19 vaccine knowledge, attitudes, and practices longitudinally in a large population of essential workers with high occupational COVID-19 exposure. The prospective design allowed for assessment of vaccination intent as well as vaccine uptake. We found KAP responses were strongly associated with vaccine uptake. Our cohort largely reported more positive attitudes toward the COVID-19 vaccine than other national

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

cohorts, <sup>12-15</sup> with more than two-thirds of participants expressing strong intent to be vaccinated. We also found strong associations between KAP responses and vaccine intention groups, with vaccine reluctant participants more likely to have negative attitudes towards safety and effectiveness and less likely to be vaccinated. While we found that a substantial proportion of our high-risk cohort population reported an initial reluctance to receive COVID-19 vaccine, ultimately one quarter of those reluctant were vaccinated by May 19, 2021. **Vaccine Reluctance.** First responders and participants with prior SARS-CoV-2 infection were more likely to be reluctant to receive the COVID-19 vaccine than other groups. First responders had the highest percentage of vaccine reluctant participants, especially the nonfirefighter subcategory. Among endorsers, other first responders also had the lowest vaccination rates. This hesitancy towards the vaccine was also represented in lower perceptions of vaccine safety, effectiveness, and trust in government. Participants with prior SARS-CoV-2 infection were less likely to receive the COVID-19 vaccine and make up more than one-third of the vaccine reluctant group and one-quarter of the reachable group. It is not surprising that participants previously positive for COVID-19 are less concerned about getting sick again, but better understanding why they report fewer positive attitudes toward vaccine safety and effectiveness will be important in persuading them to get vaccinated. 22,23 Additional studies highlighting the benefits of vaccination for those with prior infection, may help to stress the importance of vaccination among this group.<sup>24</sup> These findings are consistent with other vaccine acceptability studies done nationally 14,19 and suggest that these negative attitudes persisted even after more data became available on the safety and efficacy of available vaccines.

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

KAPs and Vaccine Uptake. Across intent to vaccinate, demographics, occupation, and prior SARS-CoV-2 infection groups, three KAP domains were consistently correlated with intent to vaccinate and vaccine uptake: safety, effectiveness, and the chance of getting sick if not vaccinated. We found knowledge about the SARS-CoV-2 virus, or the COVID-19 vaccine had no association with vaccine uptake. It is difficult to ascertain whether participants who perceive themselves to be knowledgeable are truly informed, but attitudes about vaccine safety and effectiveness appear to be more informative of individual intentions to vaccinate. Vaccination efforts that highlight vaccine safety and effectiveness may have a stronger influence on vaccination uptake than general or historical information. We found positive attitudes align with vaccine uptake and imply that KAP assessments to gauge a population's intentions or concerns in advance of vaccination campaigns is critical. Unsurprisingly, the majority of HCP were endorsers of the vaccine, and the vast majority received the COVID-19 vaccine. Some HCP occupational groups have low vaccination coverage nationally, <sup>17,18</sup> and so our study population may not be representative of those groups. Other frontline workers, which for this study included teachers, retail workers, and manufacturing were not as positive towards the vaccine as HCP, though the vast majority were still considered endorsers and reachable and were vaccinated at higher rates than first responders. The COVID-19 pandemic has clearly demonstrated the critical nature of the essential worker role and need for additional investigations. **KAP Change Over Time.** Utilizing the prospective cohort, we were able to examine shifts in KAP over time, subgrouping vaccinated versus unvaccinated participants. The KAP factors that were most connected to vaccination remained influential over time. We identified more positive shifts in responses between the two time points in those participants ultimately

vaccinated, specifically in response to perceived safety and effectiveness across all intention groups. Interestingly, even those participants that were not vaccinated demonstrated a positive increase in perceived vaccine safety and effectiveness over the three-month period.

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

Our findings are consistent with other studies conducted prior to COVID-19 vaccine authorization and availability. <sup>14,16</sup> While vaccine intent was assessed in our study after the FDA granted EUA, our findings capture an initial uncertainty that was seemingly overcome with time and positive findings for vaccine safety and effectiveness. <sup>12</sup>

**Limitations.** This study is subject to several limitations. First, the follow-up surveys were spread out over about six weeks due to site's individual IRB timelines. As the level of information available evolved quickly during the study period, participants at sites where the follow-up surveys were administered later may have had access to a meaningfully different amount, or quality, of information. Secondly, all KAPs are self-reported and there may be a disconnect between perceived knowledge and actual level of knowledge. Next, while we are confident KAPs are successfully captured in our cohorts at the time of administration, due to the novelty of the COVID-19 vaccine, KAPs will likely continue to change and evolve past this analysis period. Finally, the mechanism prompting change in KAPs is not captured, so it is difficult to know why certain KAPs changed as they did over time, e.g., the change in certain KAPs between the two follow-up surveys may have been due to increased numbers of participants receiving the vaccine with few documented serious adverse event rates, increased access to information and disease/vaccine literacy, changes in national and local COVID-19 incidence. The demographic characteristics of the group that answered Follow-up 2 different slightly from those that completed Follow-up 1: there were more female participants (64% vs 60%), they were older (45% 40-65 years of age compared to 36%), and there were higher

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

Personnel

percentages of FW (36% vs 20%) and lower percentages of HCP (44% vs 58%). Race/ethnicity, education, and income were similar between the two groups. We did not differentiate between individual COVID-19 vaccine products in this analysis. PUBLIC HEALTH IMPLICATION The HEROES-RECOVER cohort provides valuable insight into the perceptions and intentions of essential workers receiving the COVID-19 vaccine. With the current increase in cases, encouraging high-risk occupational groups to receive the COVID-19 vaccine is a critical next step. Our findings indicate that perceptions of the COVID-19 vaccine can shift over time and suggest that focusing on clear messages about the vaccine's safety and effectiveness in reducing SARS-CoV-2 virus infection and illness severity may increase vaccine uptake for reluctant and reachable participants. Targeted messaging by key stakeholders and healthcare providers for participants with prior infection and in occupations with low vaccine coverage and low trust in the government (like first responders) would be especially useful. LIST OF ABBREVATIONS **FDA** U.S. Food and Drug Administration **CDC** Centers for Disease Control and Prevention **EUA** Emergency Use Authorization **KAP** Knowledge, attitudes, and practices **HEROES** Arizona Healthcare, Emergency Response and Other Essential Workers Surveillance **RECOVER** Study and Research on the Epidemiology of SARS-CoV-2 in Essential Response

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

H-R HEROES-RECOVER **HCP** Health care personnel **FW** Frontline workers **PPE** Personal protective equipment **Disclosures:** The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Allison L. Naleway reported funding from Pfizer for a meningococcal B vaccine study unrelated to the submitted work. Statement of Contributions: K Lutrick, H Groom, A Fowlkes, K Groover, P Rivers, K Nguyen, M Herring, J Mayo Lamberte, K Prather, and S Yoon conceptualized the study and drafted the manuscript with the help of Z Baccam. J Parker and P Rivers conducted the statistical analysis. M Gaglani, A Naleway, K Dunnigan, A Phillips, M Thiese, and H Tyner were responsible for review and revision of the manuscript. All authors read and approved of the final manuscript. **Acknowledgements:** Supported by the National Center for Immunization and Respiratory Diseases and the Centers for Disease Control and Prevention (contracts 75D30120R68013 to Marshfield Clinic Research Institute, 75D30120C08379 to the University of Arizona, and 75D30120C08150 to Abt Associates). Mark G. Thompson, Lauren Grant, Young M. Yoo, Gregory Joseph, Josephine Mak, Monica Dickerson, Suxiang Tong, John Barnes, Eduardo Azziz-Baumgartner, Melissa L. Arvay, Preeta

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

Kutty, Alicia M. Fry, Lenee Blanton, Jill Ferdinands, Anthony Fiore, Aron Hall, Adam MacNeil, L. Clifford McDonald, Mary Reynolds, Sue Reynolds, Stephanie Schrag, Nong Shang, Robert Slaughter, Matthew J. Stuckey, Natalie Thornburg, Jennifer Verani, Vic Veguilla, Rose Wang, Bao-Ping Zhu, William Brannen, Stephanie Bialek, CDC; Jefferey L. Burgess, Shawn Beitel, Patrick Rivers, Xiaoxiao Sun, Joe K. Gerald, Katherine Ellingson, Ed Bedrick, Janko Nikolich-Žugich, Genesis Barron, Dimaye Calvo, Esteban Cardona, Andrea Carmona, Alissa Coleman, Emily Cooksey, Kiara Earley, Natalie Giroux, Sofia Grijalva, Allan Guidos, Adrianna Hernandez, James Hollister, Theresa Hopkins, Rezwana Islam, Krystal Jovel, Olivia Kavanagh, Jonathan Leyva, Sally Littau, Amelia Lobos, James Lopez, Veronica Lugo, Jeremy Makar, Taylor Maldonado, Enrique Marquez, Allyson Munoz, Assumpta Nsengiyunva, Joel Parker, Jonathan Perez Leyva, Alexa Roy, Saskia Smidt, Isabella Terrazas, Tahlia Thompson, Heena Timsina, Erica Vanover, Mandie White, April Yingst, Kenneth Komatsu, Elizabeth Kim, Karla Ledezma, University of Arizona, Arizona Department of Health Services; David Engelthaler, Translational Genomics Research Institute; Lauren E.W. Olsho, Danielle R. Hunt, Laura J. Edwards, Meredith G. Wesley, Tyler C. Morrill, Brandon P. Poe, Brian Sokol, Andrea Bronaugh, Tana Brummer, Hala Deeb, Rebecca Devlin, Sauma Doka, Tara Earl, Jini Etolue, Deanna Fleary, Jessica Flores, Chris Flygare, Isaiah Gerber, Louise Hadden, Jenna Harder, Lindsay LeClair, Nancy McGarry, Peenaz Mistry, Steve Pickett, Khaila Prather, David Pulaski, Rajbansi Raorane, Meghan Shea, John Thacker, Matthew Trombley, Pearl Zheng, Chao Zhou, Abt Associates; Spencer Rose, Tnelda Zunie, Michael E. Smith, Kempapura Murthy, Nicole Calhoun, Claire Mathenge, Arundhati Rao, Manohar Mutnal, Linden Morales, Shelby Johnson, Alejandro Arroliga, Madhava Beeram, Joel Blais, Jason Ettlinger, Angela Kennedy, Natalie Settele, Rupande Patel, Elisa Priest, Jennifer Thomas, Baylor Scott & White Health; Jennifer L.

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

Kuntz, Yolanda Prado, Daniel Sapp, Mi Lee, Chris Eddy, Matt Hornbrook, Danielle Millay, Dorothy Kurdyla, Ambrosia Bass, Kristi Bays, Kimberly Berame, Cathleen Bourdoin, Carlea Buslach, Jennifer Gluth, Kenni Graham, Tarika Holness Enedina Luis, Abreeanah Magdaleno, DeShaun Martin, Joyce Smith-McGee, Martha Perley, Sam Peterson, Aaron Piepert, Krystil Phillips, Joanna Price, Sperry Robinson, Katrina Schell, Emily Schield, Natosha Shirley, Anna Shivinsky, Britta Torgrimson-Ojerio, Brooke Wainwright, Shawn Westaway, Kaiser Permanente Northwest; Jennifer Meece, Elisha Stefanski, Lynn Ivacic, Jake Andreae, Adam Bissonnette, Krystal Boese, Michaela Braun, Cody DeHamer, Timothy Dziedzic, Joseph Eddy, Heather Edgren, Wayne Frome, Nolan Herman, Mitchell Hertel, Erin Higdon, Rosebud Johnson, Steve Kaiser, Tammy Koepel, Sarah Kohn, Taylor Kent, Thao Le, Carrie Marcis, Megan Maronde, Isaac McCready, Nidhi Mehta, Daniel Miesbauer, Anne Nikolai, Brooke Olson, Lisa Ott, Cory Pike, Nicole Price, Christopher Reardon, Logan Schafer, Rachel Schoone, Jaclyn Schneider, Tapan Sharma, Melissa Strupp, Janay Walters, Alyssa Weber, Reynor Wilhorn, Ryan Wright, Benjamin Zimmerman, Marshfield Clinic Research Laboratory; Angela Hunt, Jessica Lundgreen, Karley Respet, Jennifer Viergutz, Daniel Stafki, St. Luke's Regional Health Care System; Alberto J. Caban-Martinez, Natasha Schaefer-Solle, Paola Louzado Feliciano, Carlos Silvera, Karla Montes, Cynthia Beaver, Katerina Santiago, University of Miami; Rachel T. Brown, Camie Schaefer, Arlyne Arteaga, Matthew Bruner, Daniel Dawson, Emilee Eden, Jenna Praggastis, Joseph Stanford, Jeanmarie Mayer, Marcus Stucki, Riley Campbell, Kathy Tran, Madeleine Smith, Braydon Black, Madison Tallman, Chapman Cox, Derrick Wong, Michael Langston, Adriele Fugal, Fiona Tsang, Maya Wheeler, Gretchen Maughan, Taryn Hunt-Smith, Nikki Gallacher, Anika DSouza, Trevor Stubbs, Iman Ibrahim, Ryder Jordin, University of Utah; Marilyn J. Odean, Whiteside Institute for Clinical Research; Allen Bateman, Erik Reisdorf,

- 475 Kyley Guenther, Erika Hanson, Wisconsin State Laboratory of Hygiene; the HEROES-
- 476 RECOVER participants.

478

#### REFERENCES

479

- 481 1. Centers for Disease Control and Prevention. COVID-19.
- 482 <a href="https://www.cdc.gov/coronavirus/2019-ncov/index.html">https://www.cdc.gov/coronavirus/2019-ncov/index.html</a>. Accessed May 25, 2021.
- 483 2. US Food & Drug Administration. Pfizer-BioNTech COVID-19 Vaccine.
- https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine. Accessed May 25, 2021.
- 486 3. Cheng VC, Wong SC, Yuen KY. Estimating Coronavirus Disease 2019 Infection Risk in Health Care Workers. *JAMA Netw Open.* 2020;3(5):e209687.
- 488 4. Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-489 care workers and the general community: a prospective cohort study. *The Lancet Public Health*. 2020;5(9):e475-e483.
- 491 5. Rao A, Ma H, Moloney G, et al. A disproportionate epidemic: COVID-19 cases and deaths among essential workers in Toronto, Canada. *medRxiv*. 2021.
- Centers for Disease Control and Prevention. Interim List of Categories of Essential
   Workers Mapped to Standardized Industry Codes and Titles.
- 495 <a href="https://www.cdc.gov/vaccines/covid-19/categories-essential-workers.html">https://www.cdc.gov/vaccines/covid-19/categories-essential-workers.html</a>. Accessed June 1, 2021.
- Dooling K, McClung N, Chamberland M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020. MMWR Morb Mortal Wkly Rep.
   2020;69(49):1857-1859.
- 501 8. Centers for Disease Control and Prevention. COVID data tracker: COVID-19
  502 vaccinations in the United States. <a href="https://covid.cdc.gov/covid-data-tracker/#vaccinations">https://covid.cdc.gov/covid-data-tracker/#vaccinations</a>.
  503 Published 2021. Accessed May 10, 2021.
- 504 9. Wood S, Schulman K. Beyond Politics Promoting Covid-19 Vaccination in the United States. *N Engl J Med.* 2021;384(7):e23.
- 506 10. Kaiser Family Foundation. Coronavirus (COVID-19). KFF COVID-19 vaccine monitor:. Kaiser Family Foundation. <a href="https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/">https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/</a>. Published 2020. Accessed May 10, 2021.
- 509 11. Funk C TA. Intent to Get a COVID-19 Vaccine Rises to 60% as Confidence in Research510 and Development Process Increases. Pew Research Center.
- 511 <a href="https://www.pewresearch.org/science/2020/12/03/intent-to-get-a-covid-19-vaccine-rises-to-60-as-confidence-in-research-and-development-process-increases/">https://www.pewresearch.org/science/2020/12/03/intent-to-get-a-covid-19-vaccine-rises-to-60-as-confidence-in-research-and-development-process-increases/</a>. Published 2020.
   513 Accessed May 25, 2021.
- Nguyen KH, Srivastav A, Razzaghi H, et al. COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination United States, September and December 2020. MMWR Morb Mortal Wkly Rep.
   2021:70(6):217-222.
- 518 13. Ruiz JB, Bell RA. Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey. *Vaccine*. 2021;39(7):1080-1086.
- 520 14. Caban-Martinez AJ, Silvera CA, Santiago KM, et al. COVID-19 Vaccine Acceptability 521 Among US Firefighters and Emergency Medical Services Workers: A Cross-Sectional
- 522 Study. *Journal of occupational and environmental medicine*. 2021;63(5):369.

- 523 15. Pogue K, Jensen JL, Stancil CK, et al. Influences on attitudes regarding potential COVID-19 vaccination in the United States. *Vaccines*. 2020;8(4):582.
- 525 16. Biswas N, Mustapha T, Khubchandani J, Price JH. The Nature and Extent of COVID-19 Vaccination Hesitancy in Healthcare Workers. *J Community Health*. 2021.
- Shaw J, Stewart T, Anderson KB, et al. Assessment of US health care personnel (HCP)
   attitudes towards COVID-19 vaccination in a large university health care system. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*. 2021.
- 531 18. Gadoth A, Halbrook M, Martin-Blais R, et al. Assessment of COVID-19 vaccine acceptance among healthcare workers in Los Angeles. *Medrxiv*. 2020.
- Halbrook M, Gadoth A, Martin-Blais R, et al. Longitudinal assessment of COVID-19
   vaccine acceptance and uptake among frontline medical workers in Los Angeles,
   California. Clinical Infectious Diseases. 2021.
- 536 20. Akarsu B, Canbay Ozdemir D, Ayhan Baser D, Aksoy H, Fidanci I, Cankurtaran M.
  537 While studies on COVID-19 vaccine is ongoing, the public's thoughts and attitudes to the future COVID-19 vaccine. *Int J Clin Pract*. 2021;75(4):e13891.
- Lutrick K EK, Baccam Z, Rivers P, Beitel S, Parker J, Hollister J, Sun X, Gerald JK,
   Komatsu K, Kim E, LaFleur B, Grant L, Yoo YM, Kumar A, Mayo Lamberte J, Cowling
   BJ, Cobey S, Thornburg NJ, Meece JK, Kutty P, Nikolich-Zugich J, Thompson MG,
   Burgess JL. COVID-19 Infection, Reinfection, and Vaccine Effectiveness in a
   Prospective Cohort of Arizona Frontline/Essential Workers: The AZ HEROES Research
   Protocol. JMIR research protocols. 2021;26/05/2021:28923.
- Taylor S, Landry CA, Paluszek MM, Groenewoud R, Rachor GS, Asmundson GJ. A proactive approach for managing COVID-19: the importance of understanding the motivational roots of vaccination hesitancy for SARS-CoV2. *Frontiers in psychology*. 2020;11:2890.
- 549 23. Goldberg Y, Mandel M, Woodbridge Y, et al. Protection of previous SARS-CoV-2 550 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide 551 experience from Israel. *medRxiv*. 2021.
- 552 24. Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive 553 persons after a single dose of SARS-CoV-2 mRNA vaccine. *New England Journal of* 554 *Medicine*. 2021;384(14):1372-1374.

# **TABLES & FIGURES**

# Table 1. Knowledge, Attitude, and Practice (KAP) Questions

Topic	Question Text	Range
<b>Vaccine Intention</b>	What are the chances that you will get a COVID-19 vaccination?	8-point Likert (1=Don't know, 8=Almost certain)
Chance of getting sick if not vaccinated	If you are unable to or don't get a COVID-19 vaccination, what do you think your chance of getting sick with COVID-19 this year will be?	7-point Likert (1=Almost zero,
Virus Knowledge	How much do you know about the SARS-CoV-2 (COVID-19) virus and the illness it causes?	5-point Likert (1=Nothing at all, 5=A great deal)
Vaccine Knowledge	How much do you know about the COVID-19 vaccine? Would you say?	5-point Likert (1=Nothing at all, 5=A great deal)
Vaccine Safety	How safe do you think the COVID-19 vaccine is?	5-point Likert (1=Not at all, 5=Extremely safe)
Vaccine Effectiveness	How effective do you think the COVID-19 vaccine is in preventing you from getting sick with COVID-19?	5-point Likert (1=Not at all, 5=Extremely effective)
Trust in government	I trust what the government says about the COVID-19 vaccine	5-point Likert (1=Strongly disagree, 5=Strongly agree)

Table 2. Descriptive Statistics, Stratified by Vaccine Intent Group in a Survey of Essential Workers December 2020 through May 2021

	TOTAL N (%)	Reluctant N (%)	Reachable N (%)	Endorser <sup>a</sup> N (%)	P-value
Totals	4803 (100%)	653 (13.6%)	770 (16.0%)	3380 (70.4%)	
Socio-demographic Characteristics Gender*					0.03
Female	2960 (61.3%)	387 (59.3%)	513 (66.6%)	2060 (60.9%)	0.03
Male	1827 (37.8%)		255 (33.1%)		
Age (years)	1627 (37.6%)	265 (40.6%)	255 (55.1%)	1307 (38.7%)	< 0.01
18-24	143 (3.0%)	24 (2.70/)	22 (4 20/)	87 (2.6%)	<0.01
25-44	2651 (54.9%)	24 (3.7%) 358 (54.8%)	32 (4.2%) 449 (58.3%)	1844 (54.6%)	
45-64	1908 (39.5%)	259 (39.7%)	265 (34.4%)	1384 (40.9%)	
43-04 65+	1908 (39.3%)	12 (1.8%)	24 (3.1%)	65 (1.9%)	
Race/Ethnicity*	101 (2.170)	12 (1.870)	24 (3.170)	03 (1.9%)	< 0.001
Non-Hispanic-White	2440 (71 404)	431 (66.0%)	525 (69 20/)	2493 (73.8%)	<0.001
African American	3449 (71.4%) 90 (1.9%)	18 (2.8%)	525 (68.2%) 23 (3.0%)	49 (1.4%)	
Asian Am./Island Pacific	141 (2.9%)	14 (2.1%)	13 (1.7%)	` ′	
				114 (3.4%)	
Hispanic-White	694 (14.4%)	117 (17.9%)	121 (15.7%)	456 (13.5%)	
Multi-Racial/Other  Education*	429 (8.9%)	73 (11.2%)	88 (11.4%)	268 (7.9%)	< 0.001
	154 (2.20/)	25 (5 40/)	40 (5 20/)	70 (2.2%)	<0.001
Less than college	154 (3.2%)	35 (5.4%)	40 (5.2%) 201 (26.1%)	79 (2.3%)	
Some college College degree or above	856 (17.7%)	186 (28.5%)	` /	469 (13.9%) 2759 (81.6%)	
Annual Income*	3685 (76.3%)	413 (63.2%)	513 (66.6%)	2739 (81.0%)	< 0.001
	702 (14 60/)	129 (10 (0))	152 (10.70()	422 (12 50/)	<0.001
< 50 k 50k-100k	702 (14.6%)	128 (19.6%)	152 (19.7%)	422 (12.5%)	
100k+	1955 (40.7%)	244 (37.4%)	280 (36.4%)	898 (26.6%)	
	2000 (41.6%)	261 (40.0%)	317 (41.2%)	1965 (58.1%)	-0.001
Occupation  HCP impatient	1105 (22 00/)	100 (15 20/)	115 (14 00/)	200 (26 20/)	< 0.001
HCP inpatient HCP other	1105 (22.9%)	100 (15.3%)	115 (14.9%)	890 (26.3%)	
	1323 (27.4%)	148 (22.7%)	163 (21.2%)	1012 (29.9%)	
First responder firefighter First responder other	729 (15.1%) 255 (5.3%)	119 (18.2%) 54 (8.3%)	78 (10.1%) 41 (5.3%)	532 (15.7%) 160 (4.7%)	
FW public	990 (20.5%)	156 (23.9%)	261 (33.9%)	573 (17.0%)	
FW other					
	285 (5.9%)	57 (8.7%)	80 (10.4%)	148 (4.4%)	
Underlying Medical Conditions					0.000
Asthma No	4202 (99 00/ )	570 (00 50/ )	695 (90 00/)	2020 (90.6%)	0.990
	4292 (88.9%)	578 (88.5%) 59 (9.0%)	685 (89.0%)	3029 (89.6%)	
Yes Diabetes	446 (9.2%)	39 (9.0%)	72 (9.4%)	315 (9.3%)	0.920
No	4576 (04.70/)	615 (04.20/)	722 (05 20/)	2229 (05 50/)	0.920
Yes	4576 (94.7%) 162 (3.4%)	615 (94.2%) 22 (3.4%)	733 (95.2%) 24 (3.1%)	3228 (95.5%) 116 (3.4%)	
Hypertension	102 (3.4%)	22 (3.4%)	24 (3.1%)	110 (3.4%)	0.710
No	4158 (86.1%)	556 (85.1%)	659 (85.6%)	2943 (87.1%)	0.710
Yes	580 (12.0%)	81 (12.4%)	98 (12.7%)	401 (11.9%)	
Any above condition*	300 (12.070)	01 (12.470)	90 (12.770)	401 (11.970)	0.050
No	3176 (66.1%)	425 (65.1%)	502 (65.2%)	2249 (66.5%)	0.869
No Yes	1562 (32.5%)	212 (32.5%)	255 (33.1%)	1095 (32.4%)	
SARS-CoV-2 Infection Prior to Follow-Up 1	1502 (52.570)	212 (32.370)	200 (00.170)	1075 (32.470)	
Survey					< 0.001
No	3843 (79.6%)	424 (64.9%)	576 (74.8%)	2843 (84.1%)	
				` ′	

COVID-19 Vaccine received during the study					
Received Covid-19 Vaccine, Follow-up 1					
No	3083 (64.2%)	653 (100%)	770 (100%)	1660 (49.1%)	
Yes	1720 (35.8%)	0 (0%)	0 (0%)	1720 (50.9%)	
Received Covid-19 Vaccine, Follow-up 2					< 0.001
No	1332 (27.7%)	489 (74.9%)	366 (47.5%)	477 (14.1%)	
Yes	3471 (72.3%)	164 (25.1%)	404 (52.5%)	2903 (85.9%)	
Responses to KAP questions  Chances of getting sick if not vaccinated					<0.001
Negative/Neutral	2693 (55.8%)	544 (83.3%)	515 (66.9%)	1634 (48.3%)	
Positive	1985 (41.1%)	109 (16.7%)	252 (32.7%)	1624 (48.0%)	
Virus Knowledge					< 0.001
Negative/Neutral	1575 (32.8%)	282 (43.2%)	322 (41.8%)	971 (28.7%)	
Positive	3191 (66.4%)	371 (56.8%)	442 (57.4%)	2378 (70.4%)	
Vaccine Knowledge					< 0.001
Negative/Neutral	2838 (58.8%)	505 (77.3%)	582 (75.6%)	1751 (51.8%)	
Positive	1935 (40.1%)	148 (22.7%)	187 (24.3%)	1600 (47.3%)	
Vaccine Safety					< 0.001
Negative/Neutral	1825 (37.8%)	535 (81.9%)	427 (55.5%)	863 (25.5%)	
Positive	2945 (61.0%)	114 (17.5%)	343 (44.5%)	2488 (73.6%)	
Vaccine Effectiveness					< 0.001
Negative/Neutral	1825 (37.8%)	498 (76.3%)	392 (50.9%)	935 (27.7%)	
Positive	2944 (61.0%)	152 (23.3%)	375 (48.7%)	2417 (71.5%)	
Trust in the Government					< 0.001
Negative/Neutral	2371 (49.1%)	513 (78.6%)	443 (57.5%)	1415 (41.9%)	
Positive	2404 (49.8%)	140 (21.4%)	327 (42.5%)	1937 (57.3%)	

Reluctant participants indicated low likelihood of being vaccinated, Reachable participants mentioned a moderate likelihood of being unvaccinated, and Endorser participants indicated a high likelihood of being vaccinated or were already vaccinated; <sup>a</sup> People who answered the KAP questions after being vaccinated were considered endorsers to get vaccinated; <sup>b</sup> Only asked to unvaccinated participants in non-AZ sites; Likert responses were condensed from 5 to 8 categories (depending on the question) to negative/neutral and positive

<sup>\*</sup> Proportions may differ due to missing data not shown or small numbers sequestered

Table 3. Difference in Knowledge, Attitude, and Practice (KAP) Questions Stratified by Vaccination Status, Intention Group, Occupation, and Prior SARS-CoV-2 Positivity in a Cohort of Essential Workers (N=4803)<sup>a</sup>

	Unadjusted				
	OR	95% CI	OR	djusted <sup>b</sup> 95% CI	
Vaccinated during the study (not vacc	inated is th				
Virus Knowledge	1.58	1.40 – 1.79			
Vaccine Knowledge	2.49	2.17 - 2.87			
Vaccine Safety	9.81	8.42 - 11.44	5.46	1.43 - 20.82	
Vaccine Effectiveness	8.29	7.10 - 9.67	4.98	1.30 - 19.14	
Trust in government	4.40	3.87 - 5.00			
Chances of getting sick	4.15	3.58 - 4.81			
By Intention Group (Endorser is the I	reference G	roup)			
Reluctant					
Virus Knowledge	0.53	0.45 - 0.62			
Vaccine Knowledge	0.30	0.26 - 0.35	0.49	0.34 - 0.72	
Vaccine Safety	0.08	0.06 - 0.09	0.23	0.15 - 0.33	
Vaccine Effectiveness	0.12	0.10 - 0.14	0.32	0.22 - 0.48	
Trust in government	0.20	0.17 - 0.23	0.43	0.30 - 0.61	
Chances of getting sick	0.23	0.20 - 0.27	0.48	0.32 - 0.74	
Reachable					
Virus Knowledge	0.52	0.45 - 0.60			
Vaccine Knowledge	0.34	0.30 - 0.40	0.53	0.30 - 0.96	
Vaccine Safety	0.33	0.28 - 0.38	0.56	0.31 - 1.00	
Vaccine Effectiveness	0.40	0.35 - 0.47			
Trust in government	0.58	0.51 - 0.67			
Chances of getting sick	0.59	0.51 - 0.68			
Occupation (HCP inpatient is the refe	rence grou	p)			
HCP other					
Virus Knowledge	0.81	0.70 - 0.94			
Vaccine Knowledge	0.97	0.84 - 1.12			
Vaccine Safety	0.91	0.79 - 1.06			
Vaccine Effectiveness	1.02	0.87 - 1.18			
Trust in government	0.98	0.85 - 1.13			
Chances of getting sick	0.89	0.77 - 1.03			
First responder firefighter					
Virus Knowledge	0.37	0.31 - 0.44	0.48	0.39 - 0.59	
Vaccine Knowledge	0.43	0.36 - 0.51	0.57	0.46 - 0.71	
Vaccine Safety	0.43	0.36 - 0.51	0.60	0.48 - 0.74	
Vaccine Effectiveness	0.41	0.34 - 0.49	0.61	0.49 - 0.76	
Trust in government	0.62	0.52 - 0.73			
Chances of getting sick	0.72	0.61 - 0.85			
First responder other	0.20	0.15 0.05	0.05	0.10 0.26	
Virus Knowledge	0.20	0.15 - 0.25	0.25	0.18 - 0.36	
Vaccine Knowledge	0.19	0.15 - 0.25	0.34	0.24 - 0.49	
Vaccine Safety	0.34	0.26 - 0.43	0.46	0.32 - 0.67	
Vaccine Effectiveness	0.41	0.32 - 0.53	0.58	0.40 - 0.84	
Trust in government	0.48	0.37 - 0.60	0.67	0.47 - 0.95	
Chances of getting sick	0.71	0.56 - 0.91			
FW Public	0.20	0.26 0.26	0.41	0.24 0.50	
Virus Knowledge	0.30	0.26 - 0.36	0.41	0.34 - 0.50	
Vaccine Knowledge	0.30	0.25 - 0.35	0.41	0.33 - 0.50	
Vaccine Safety	0.65	0.55 - 0.76	1.25	1.00 1.52	
Vaccine Effectiveness	0.75	0.64 - 0.88	1.25	1.02 – 1.53	
Trust in government	0.95	0.82 – 1.11	1.38	1.14 – 1.68	
Chances of getting sick	0.94	0.81 - 1.10	1.33	1.13 - 1.56	
FW other	0.20	0.22 0.25	0.41	0.25 0.40	
Virus Knowledge	0.28	0.22 - 0.35	0.41	0.35 - 0.49	

Vaccine Knowledge	0.36	0.28 - 0.45	0.49	0.41 - 0.57
Vaccine Safety	0.59	0.47 - 0.75		
Vaccine Effectiveness	0.72	0.56 - 0.91	1.49	1.26 - 1.77
Trust in government	0.86	0.68 - 1.08		
Chances of getting sick	0.52	0.41 - 0.65		
Prior SARS-CoV-2 Infection (No kno	wn prior inf	ection as the refer	ence group)	
Virus Knowledge	0.91	0.85 - 0.98		
Vaccine Knowledge	0.62	0.57 - 0.68	0.78	0.64 - 0.95
Vaccine Safety	0.51	0.47 - 0.55		
Vaccine Effectiveness	0.48	0.44 - 0.52	0.78	0.64 - 0.96
Trust in government	0.62	0.58 - 0.67		
Chances of getting sick	0.46	0.42 - 0.51	0.68	0.56 - 0.84

<sup>&</sup>lt;sup>a</sup>P-values not reported due to inconsistencies that occur with multi-level categorical variables. Statistical significance based on 95% confidence intervals.

<sup>&</sup>lt;sup>b</sup> Non-significant adjusted point estimates and confidence intervals not reported. Bonferroni corrections were used for each of vaccination status, intention group, occupation, and prior positivity. The model was adjusted for socio-demographics, occupation and occupational setting, vaccine intention, and prior positivity for SARS-CoV-2 infection.

Table 4. Demographics of Vaccine Intention Groups, Stratified by Vaccination Status at Time of Follow-up Survey 2 in a Cohort of Essential Workers

	J	Reluctant		ŀ	Reachable			Endorser		
	Not Vaccinated	Vaccinated	p-value	Not Vaccinated	Vaccinated	p-value	Not Vaccinated	Vaccinated	p-value	
	(N=289)	(N=94)	1	(N=152)	(N=195)	1	(N=246)	(N=1232)	1	
Gender			0.624			0.475			0.017	
Female	168 (58.1%)	58 (61.7%)		104 (68.4%)	138 (70.8%)		133 (54.1%)	783 (63.6%)		
Male	121 (41.9%)	36 (38.3%)		47 (30.9%)	56 (28.7%)		112 (45.5%)	445 (36.1%)		
Age (years)			0.439			0.372				
18-24	11 (3.8%)	3 (3.2%)		9 (5.9%)	11 (5.6%)		10 (4.1%)	19 (1.5%)	0.014	
25-44	158 (54.7%)	44 (46.8%)		89 (58.6%)	100 (51.3%)		132 (53.7%)	596 (48.4%)		
45-64	111 (38.4%)	45 (47.9%)		50 (32.9%)	73 (37.4%)		99 (40.2%)	579 (47.0%)		
65+	9 (3.1%)	2 (2.1%)		4 (2.6%)	11 (5.6%)		5 (2.0%)	38 (3.1%)		
Race/Ethnicity			0.975			0.310			0.241	
Non-Hispanic-White	188 (65.1%)	60 (63.8%)		99 (65.1%)	125 (64.1%)		169 (68.7%)	883 (71.7%)		
African American	8 (2.8%)	3 (3.2%)		7 (4.6%)	2 (1.0%)		4 (1.6%)	13 (1.1%)		
Asian American	6 (2.1%)	2 (2.1%)		2 (1.3%)	3 (1.5%)		4 (1.6%)	30 (2.4%)		
Hispanic-White	54 (18.7%)	16 (17.0%)		26 (17.1%)	34 (17.4%)		48 (19.5%)	186 (15.1%)		
Multi-Racial	13 (4.5%)	4 (4.3%)		7 (4.6%)	16 (8.2%)		8 (3.3%)	69 (5.6%)		
Other	20 (6.9%)	9 (9.6%)		11 (7.2%)	15 (7.7%)		13 (5.3%)	51 (4.1%)		
Education	, ,	,	0.906		, ,	0.313		, ,	< 0.001	
Less than High school	0 (0%)	0 (0%)		2 (1.3%)	0 (0%)		0 (0%)	1 (0.1%)		
HS diploma/GED	15 (5.2%)	6 (6.4%)		8 (5.3%)	8 (4.1%)		11 (4.5%)	26 (2.1%)		
Some college	78 (27.0%)	25 (26.6%)		45 (29.6%)	50 (25.6%)		59 (24.0%)	140 (11.4%)		
College degree/above	187 (64.7%)	60 (63.8%)		95 (62.5%)	131 (67.2%)		172 (69.9%)	1041 (84.5%)		
Annual Income	,	` ,	0.177	` ,	` ,	0.308	` ′	` ,	< 0.001	
< 50 k	63 (21.8%)	10 (10.6%)		33 (21.7%)	32 (16.4%)		46 (18.7%)	108 (8.8%)		
50k-100k	104 (36.0%)	40 (42.6%)		47 (30.9%)	78 (40.0%)		74 (30.1%)	389 (31.6%)		
100k-150k	62 (21.5%)	22 (23.4%)		45 (29.6%)	46 (23.6%)		62 (25.2%)	328 (26.6%)		
150k-200k	27 (9.3%)	8 (8.5%)		16 (10.5%)	20 (10.3%)		35 (14.2%)	173 (14.0%)		
200k+	20 (6.9%)	9 (9.6%)		9 (5.9%)	8 (4.1%)		23 (9.3%)	194 (15.7%)		
Previously Tested Positive	,	,	0.405	,	` ,	0.003	,	,	< 0.001	
No	181 (62.6%)	64 (68.1%)		96 (63.2%)	153 (78.5%)		166 (67.5%)	1046 (84.9%)		
Yes	108 (37.4%)	30 (31.9%)		56 (36.8%)	42 (21.5%)		80 (32.5%)	186 (15.1%)		
Occupation	(,		0.749	` ,	` ',	< 0.001	` '	` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` `	< 0.001	
HCP Inpatient	45 (15.6%)	17 (18.1%)	-	30 (19.7%)	22 (11.3%)		50 (20.3%)	268 (21.8%)		
HCP Other	63 (21.8%)	16 (17.0%)		46 (30.3%)	28 (14.4%)		42 (17.1%)	321 (26.1%)		

First responder firefighter	55 (19.0%)	15 (16.0%)		20 (13.2%)	16 (8.2%)		62 (25.2%)	121 (9.8%)	
First responder other	29 (10.0%)	9 (9.6%)		5 (3.3%)	19 (9.7%)		16 (6.5%)	89 (7.2%)	
FW Public	67 (23.2%)	28 (29.8%)		36 (23.7%)	90 (46.2%)		40 (16.3%)	365 (29.6%)	
FW other	22 (7.6%)	7 (7.4%)		10 (6.6%)	17 (8.7%)		27 (11.0%)	68 (5.5%)	
Asthma			0.873			0.418			0.718
No	259 (89.6%)	85 (90.4%)		141 (92.8%)	173 (88.7%)		221 (89.8%)	1091 (88.6%)	
Yes	22 (7.6%)	6 (6.4%)		9 (5.9%)	17 (8.7%)		22 (8.9%)	122 (9.9%)	
Diabetes			0.565			0.217			0.409
No	274 (94.8%)	87 (92.6%)		148 (97.4%)	182 (93.3%)		237 (96.3%)	1167 (94.7%)	
Yes	7 (2.4%)	4 (4.3%)		2 (1.3%)	8 (4.1%)		6 (2.4%)	46 (3.7%)	
Hypertension			0.571			0.835			0.541
No	252 (87.2%)	79 (84.0%)		129 (84.9%)	166 (85.1%)		216 (87.8%)	1058 (85.9%)	
Yes	29 (10.0%)	12 (12.8%)		21 (13.8%)	24 (12.3%)		27 (11.0%)	155 (12.6%)	

medRxiv preprint doi: https://doi.org/10.1101/2021.10.20.21265288; this version posted October 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.


All rights reserved. No reuse allowed without permission.

Table 5. Change in Positive Response to Knowledge, Attitude, and Practice (KAP) Questions by Intention and Actual Vaccination from Follow-up Survey 1 to Follow-up Survey 2


	Virus Knowledge		Vaccine Knowledge		<b>Vaccine Safety</b>		Vaccine Effectiveness		Trust in government	
	n(%)	p-value	n(%)	p-value	n(%)	p-value	n(%)	p-value	n(%)	p-value
Reluctant										
Never Vaccinated	-26 (-9.0%)	0.044	58 (20.0%)	< 0.001	13 (4.5%)	0.170	21 (7.2%)	0.032	-5 (-1.7%)	0.635
Vaccinated	-8 (-8.5%)	0.305	20 (21.2%)	0.002	25 (26.6%)	< 0.001	29 (30.9%)	< 0.001	13 (13.8%)	0.049
Reachable										
Never Vaccinated	-29 (-19.0%)	0.001	38 (25.0%)	< 0.001	15 (9.9%)	0.044	18 (11.9%)	0.035	0 (0.0%)	1.000
Vaccinated	2 (1.0%)	0.876	49 (25.2%)	< 0.001	67 (34.4%)	< 0.001	52 (26.6%)	< 0.001	26 (13.3%)	0.011
Endorser										
Never Vaccinated	-53 (-21.5%)	< 0.001	53 (21.5%)	< 0.001	8 (3.2%)	0.476	6 (2.4%)	0.585	11 (4.4%)	0.303
Vaccinated	13 (1.1%)	0.596	235 (19.1%)	< 0.001	147 (11.9%)	< 0.001	136 (11.1%)	< 0.001	117 (9.5%)	< 0.001

## **Supplemental Appendix**

## Supplemental Figure 1. Timeline of key HEROES and RECOVER study activities July 2020-May 2021



# Supplemental Figure 2. Change in Positive Response to Knowledge, Attitude, and Practice (KAP) Questions from Follow-Up Survey 1 to Follow-Up Survey 2, by Intention and Actual Vaccination



# Supplemental Table 1. KAP by Intention group, Occupation, and prior SARS-CoV-2 Infection

	Chance of getting sick if not vaccinated	Virus Knowledge	Vaccine Knowledge	Vaccine Safety	Vaccine Effectiveness	Trust in government
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
<b>COVID-19 Vaccine Intention</b>						
Reluctant	3.47 (1.40)	3.66 (0.876)	2.97 (0.919)	2.83 (0.846)	2.98 (0.849)	2.56 (1.19)
Reachable	4.23 (1.37)	3.64 (0.851)	2.98 (0.843)	3.50 (0.805)	3.54 (0.774)	3.32 (1.14)
Endorser	4.62 (1.47)	3.95 (0.839)	3.57 (0.886)	3.93 (0.794)	3.88 (0.775)	3.64 (1.20)
Occupation						
HCP inpatient	4.54 (1.48)	4.14 (0.766)	3.62 (0.882)	3.87 (0.838)	3.83 (0.798)	3.54 (1.22)
HCP other	4.44 (1.47)	4.04 (0.805)	3.60 (0.898)	3.82 (0.884)	3.82 (0.868)	3.52 (1.26)
First responder firefighter	4.26 (1.52)	3.71 (0.833)	3.20 (0.896)	3.48 (0.907)	3.43 (0.843)	3.20 (1.24)
First responder other	4.26 (1.52)	3.40 (0.873)	2.84 (0.869)	3.35 (0.913)	3.43 (0.860)	3.02 (1.24)
FW public	4.49 (1.51)	3.61 (0.861)	3.04 (0.859)	3.68 (0.875)	3.70 (0.812)	3.50 (1.22)
FW other	4.00 (1.46)	3.57 (0.868)	3.11 (0.840)	3.66 (0.845)	3.70 (0.800)	3.43 (1.25)
<b>Prior SARS-CoV-2 Infection</b>						
No	4.52 (1.43)	3.87 (0.848)	3.40 (0.912)	3.78 (0.867)	3.77 (0.813)	3.51 (1.23)
Yes	3.91 (1.67)	3.82 (0.885)	3.17 (0.935)	3.46 (0.916)	3.44 (0.897)	3.18 (1.25)

All relationships were tested by Chi-square test and are statistically significant at p<0.001 so omitted for clarity